[Translation] A single-arm, open-label, single-dose, multicenter Phase I/II clinical study to evaluate the safety and efficacy of autologous CRISPR-Cas9-edited CD34-positive cells (RM-001 cell injection) in the treatment of transfusion-dependent β-thalassemia
评价RM-001细胞注射液治疗输血依赖型β-地中海贫血的安全性和有效性的多中心、开放的临床研究。
[Translation]
A multicenter, open clinical study to evaluate the safety and efficacy of RM-001 cell injection in the treatment of transfusion-dependent β-thalassemia.
Literatures (Medical) associated with Guangzhou Ruifeng Biological Technology Co., Ltd.
HemaSphere
P1465: INITIAL SAFETY AND EFFICACY STUDY OF RM-001, AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS, IN TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA
Author: Wang, L. ; Liang, J. ; Xiao, B. ; Shi, L. ; Huang, J. ; Xu, H. ; Zhang, X. ; Li, Y. ; Xu, X.
100 Deals associated with Guangzhou Ruifeng Biological Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Guangzhou Ruifeng Biological Technology Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.